Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
暂无分享,去创建一个
Wing W. Chan | S. Solomon | J. McMurray | J. Rouleau | G. Fonarow | M. Zile | B. Claggett | T. Gaziano | S. Turner | C. Deschaseaux-Voinet | W. Chan
[1] G. Sanders,et al. Cost-Effectiveness in Health and Medicine , 2016 .
[2] R. Nelson,et al. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. , 2016, JACC. Heart failure.
[3] S. Solomon,et al. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. , 2015, The New England journal of medicine.
[4] G. Fonarow,et al. Factors associated with variations in hospital expenditures for acute heart failure in the United States. , 2015, American heart journal.
[5] Mark D. Huffman,et al. AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .
[6] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.
[7] Joel Stein,et al. Heart Disease and Stroke Statistics – At-a-Glance , 2015 .
[8] John B. Wong,et al. Decision making in health and medicine: Integrating evidence and values, second edition , 2014 .
[9] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[10] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[11] G. Fonarow,et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Circulation.
[12] Zhang Shu-jian. Cost-Effectiveness of percutaneous coronary Intervention in patients with stable coronary artery disease and abnormal fractional flow reserve , 2014 .
[13] P. Jüni,et al. Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow Reserve Interventional Cardiology , 2022 .
[14] L. Goldraich,et al. Cost-effectiveness of heart failure therapies , 2013, Nature Reviews Cardiology.
[15] D. McManus,et al. Improved Survival After Heart Failure: A Community‐Based Perspective , 2013, Journal of the American Heart Association.
[16] J. Haerting,et al. Prevalence of Symptomatic Heart Failure with Reduced and with Normal Ejection Fraction in an Elderly General Population–The CARLA Study , 2013, PloS one.
[17] David Thompson,et al. Cost Estimation of Cardiovascular Disease Events in the US , 2011, PharmacoEconomics.
[18] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[19] M. Roizen. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2012 .
[20] C. O'connor,et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. , 2008, JAMA.
[21] Milton C Weinstein,et al. Heart failure disease management programs: a cost-effectiveness analysis. , 2008, American heart journal.
[22] G. Lamas,et al. Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM , 2007, European journal of heart failure.
[23] Audrey J Weiss,et al. Overview of Hospital Stays in the United States, 2012 , 2012 .
[24] T. Gaziano,et al. Cardiovascular Disease in the Developing World and Its Cost-Effective Management , 2005, Circulation.
[25] O. Franco,et al. Cost effectiveness of statins in coronary heart disease , 2005, Journal of Epidemiology and Community Health.
[26] Douglas K Owens,et al. Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.
[27] Graham Nichol,et al. Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Symptomatic Heart Failure , 2004, Annals of Internal Medicine.
[28] S Capewell,et al. More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.
[29] L. Prosser,et al. Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics , 2000, Annals of Internal Medicine.
[30] G. Oster,et al. Cost effectiveness of carvedilol for heart failure. , 1999, The American journal of cardiology.
[31] D. Huse,et al. Cost-effectiveness of statins. , 1998, The American journal of cardiology.
[32] M. Mcgrath. Cost Effectiveness in Health and Medicine. , 1998 .
[33] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine , 1997 .